Company Overview

Madrigal Pharmaceuticals, Inc. is a leading biopharmaceutical company dedicated to developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with a significant unmet medical need. Headquartered in West Conshohocken, Pennsylvania, Madrigal's flagship medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target the key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3).

The company's strategic focus is on addressing the substantial patient population affected by MASH, a condition that affects millions globally and poses a growing public health challenge.

Key Drug: Rezdiffra

Rezdiffra represents a significant breakthrough in MASH treatment, addressing a critical unmet medical need in liver disease. The therapy received accelerated approval from the U.S. Food and Drug Administration (FDA), in conjunction with diet and exercise, for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). It is also being evaluated in an ongoing Phase 3 outcomes trial for the treatment of MASH with compensated cirrhosis (consistent with stage F4c).

The drug has demonstrated compelling clinical results. In February, Madrigal announced two-year results indicating that patients achieved a mean 6.7 kPa reduction in liver stiffness, as measured by vibration-controlled transient elastography (VCTE), which was statistically significant compared to baseline. Notably, 51% of patients achieved a ≥ 25% reduction in liver stiffness by VCTE, a magnitude of reduction associated with a lower risk of progression to end-stage liver disease.

Financial Performance

Q2 2025 Performance

The standout news in this period was an impressive surge in GAAP revenue to $212.8 million, significantly exceeding the consensus estimate of $162.03 million. This represents tremendous growth for the company as it commercializes its groundbreaking therapy.

Q1 2025 Performance

Rezdiffra's net sales reached $137 million in Q1 2025 alone, demonstrating the drug's rapid adoption and strong patient uptake since its launch.

Revenue Growth

As of May 2025, Madrigal Pharmaceuticals' trailing twelve months (TTM) revenue stood at approximately $0.31 billion USD. For the full year 2024, the company reported revenue of $0.18 billion USD, indicating substantial year-over-year growth.

Commercial Success and Patient Adoption

The commercial launch of Rezdiffra has exceeded initial expectations. By June 30, 2025, over 23,000 patients were on Rezdiffra, a notable increase from more than 17,000 as of March 31, 2025, and from 11,800 at the end of Q4 2024. Considering the targeted U.S. specialist-treated patient population of approximately 315,000, this rapid pace signifies substantial early adoption.

Healthcare provider acceptance has been robust. Among Madrigal's top 6,000 specialist targets, approximately 70% had prescribed Rezdiffra by the end of Q1 2025. Within the broader pool of 14,000 target prescribers, about half had prescribed the drug by the end of Q1 2025.

Financial Position

Madrigal's cash, cash equivalents, restricted cash, and marketable securities totaled $802.0 million as of June 30, 2025, a decrease from $931.3 million as of December 31, 2024. However, the company secured up to $500 million in new senior secured credit from Blue Owl Capital during July, including an initial $350 million draw. This financing strengthens the company's financial runway, providing substantial resources for continued growth and development.

Pipeline and Future Developments

European Expansion

In August 2025, Madrigal announced that it received European Commission Approval for Rezdiffra™ (resmetirom) for the treatment of MASH with moderate to advanced liver fibrosis. With regulatory decisions anticipated in Europe by year-end 2025 and plans to launch in Germany during the same period, the company is strategically positioned to replicate its U.S. success in a market with over 10 million potential MASH patients.

Research Pipeline

In July, Madrigal announced a licensing agreement with CSPC Pharma for global rights to SYH2086, an oral glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. This license agreement supports Madrigal's strategy to develop innovative combination treatments for MASH, complementing its foundational therapy, Rezdiffra. SYH2086 is expected to enter clinical development in the first half of 2026.

Ongoing Clinical Trials

An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). The preliminary results further support the potential benefit of Rezdiffra in patients with compensated MASH cirrhosis and the ongoing MAESTRO-NASH OUTCOMES trial, a double-blind, placebo-controlled, event-driven trial in F4c patients, for which data are anticipated in 2027.

Intellectual Property Protection

The U.S. Patent and Trademark Office (USPTO) is expected to issue a new patent (U.S. Patent No. 12,377,104) entitled "Methods for treating a fatty liver disease." This patent covers the FDA-approved use of Rezdiffra, with claims directed to its commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. This patent extends protection until 2045, ensuring long-term commercial exclusivity for the company's flagship therapy.

Market Opportunity

The MASH market presents a significant opportunity, characterized by high unmet medical needs. Madrigal's first-mover advantage, combined with its robust cash reserves and clinically differentiated therapy, positions it strongly to outpace competitors. The company has firmly established itself as a pioneer in this therapeutic area with the first approved treatment for MASH.

Madrigal Pharmaceuticals has successfully transitioned from a clinical-stage biotechnology company to a commercial success story, demonstrating strong execution in both drug development and commercialization. With Rezdiffra's proven efficacy, expanding patient base, and upcoming international expansion, the company is well-positioned for sustained growth within the evolving MASH treatment landscape.